Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report

Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Akagi, Yuina, Yamashita, Yusuke, Kosako, Hideki, Furuya, Yoshiaki, Hosoi, Hiroki, Mushino, Toshiki, Murata, Shogo, Nishikawa, Akinori, Tamura, Shinobu, Nakao, Taisei, Sonoki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435694/
https://www.ncbi.nlm.nih.gov/pubmed/37601888
http://dx.doi.org/10.1002/jha2.732
_version_ 1785092159667437568
author Akagi, Yuina
Yamashita, Yusuke
Kosako, Hideki
Furuya, Yoshiaki
Hosoi, Hiroki
Mushino, Toshiki
Murata, Shogo
Nishikawa, Akinori
Tamura, Shinobu
Nakao, Taisei
Sonoki, Takashi
author_facet Akagi, Yuina
Yamashita, Yusuke
Kosako, Hideki
Furuya, Yoshiaki
Hosoi, Hiroki
Mushino, Toshiki
Murata, Shogo
Nishikawa, Akinori
Tamura, Shinobu
Nakao, Taisei
Sonoki, Takashi
author_sort Akagi, Yuina
collection PubMed
description Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73‐year‐old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis.
format Online
Article
Text
id pubmed-10435694
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104356942023-08-19 Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report Akagi, Yuina Yamashita, Yusuke Kosako, Hideki Furuya, Yoshiaki Hosoi, Hiroki Mushino, Toshiki Murata, Shogo Nishikawa, Akinori Tamura, Shinobu Nakao, Taisei Sonoki, Takashi EJHaem Case Reports Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B‐cell lymphoma‐2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73‐year‐old man with AML undergoing dialysis and who was ineligible for standard therapies. The safety of venetoclax and azacitidine in patients undergoing dialysis has been reported, and their combination may be a feasible option for patients with AML undergoing dialysis. John Wiley and Sons Inc. 2023-06-06 /pmc/articles/PMC10435694/ /pubmed/37601888 http://dx.doi.org/10.1002/jha2.732 Text en © 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Akagi, Yuina
Yamashita, Yusuke
Kosako, Hideki
Furuya, Yoshiaki
Hosoi, Hiroki
Mushino, Toshiki
Murata, Shogo
Nishikawa, Akinori
Tamura, Shinobu
Nakao, Taisei
Sonoki, Takashi
Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title_full Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title_fullStr Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title_full_unstemmed Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title_short Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
title_sort administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435694/
https://www.ncbi.nlm.nih.gov/pubmed/37601888
http://dx.doi.org/10.1002/jha2.732
work_keys_str_mv AT akagiyuina administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT yamashitayusuke administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT kosakohideki administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT furuyayoshiaki administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT hosoihiroki administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT mushinotoshiki administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT muratashogo administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT nishikawaakinori administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT tamurashinobu administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT nakaotaisei administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport
AT sonokitakashi administrationofcombinedvenetoclaxandazacitidineinapatientwithacutemyeloidleukemiaandmultiplecomorbiditiesundergoingdialysisacasereport

Ejemplares similares